Study of Out of Specification for Tisagenlecleucel
A phase 3 trial of Tisagenlecleucel in diffuse large b-cell lymphoma, run by Novartis Pharmaceuticals, now recruiting.
Overview
Study of Out of Specification for Tisagenlecleucel is a phase 3 interventional study registered as NCT04094311 by Novartis Pharmaceuticals, with 200 participants planned, started 2019-11-21 and due to reach its primary completion in 2027-03-31. Interventions recorded: CTL019. Conditions listed: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Shares Novartis, Diffuse large B-cell lymphoma.
- TrialA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Shares Novartis, Diffuse large B-cell lymphoma.
- TrialA Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Shares Tisagenlecleucel, Novartis.
- CompanyMorphoSys (Novartis)
Shares Novartis, Diffuse large B-cell lymphoma.
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares Tisagenlecleucel, Novartis, Diffuse large B-cell lymphoma.
- TreatmentVarnimcabtagene autoleucel
- PersonCarl H. June
- Key paperMaude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL
Shares Tisagenlecleucel, Novartis.